Disease Areas

Woman in blue shirt holding a baby and kissing him on the forehead

The potential to transform the lives of patients drives us at Biogen

Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialised immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. 

Find out more about our disease areas below.

Alzheimer’s Disease and Dementia

Our world-class neurology research and development organisation is pushing toward novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.

Amyotrophic Lateral Sclerosis (ALS)

For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 352,000 people worldwide1,2.


Depression affects an estimated one in six people in the UK3 and postpartum depression symptoms are estimated to affect one in ten women who have given birth in the UK4. We are fearless in advancing the treatment of depression to support those living with or impacted by this diagnosis.

Friedreich’s Ataxia

Friedreich Ataxia is a genetic, debilitating and life-shortening neuromuscular disease, affecting approximately 15,000 individuals globally5.

Multiple Sclerosis (MS)

Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS.

Spinal Muscular Atrophy (SMA)

Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. Spinal Muscular Atrophy (SMA) is a genetic, progressive, life-limiting rare disease that affects an individual’s ability to walk, eat, and, ultimately, breathe. Debilitating and often fatal, SMA affects approximately one in 10,000 individuals and is the leading genetic cause of death among infants6,7.

  1. Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, Zhan S, Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944-953. doi: 10.1007/s00415-019-09652-y. Epub 2019 Dec 3. PMID: 31797084. Available at: https://pubmed.ncbi.nlm.nih.gov/31797084/ Last accessed: January 2024
  2. United Nations, World population prospects: The 2010 revision (2022). New York. Available at: World Population Prospects - Population Division - United Nations Last accessed: January 2024
        a.     * Calculated based on prevalence estimates
  3. Depression Statistics UK 2023. Available at: https://championhealth.co.uk/insights/depression-statistics/ Last accessed: January 2024
  4. Postpartum Depression Statistics I Recent Research and Data About PPD Available at: https://www.postpartumdepression.org/resources/statistics/ Last accessed: January 2024
  5. Friedreich's Ataxia Research Alliance - What is FA? Available at: https://www.curefa.org/what-is-friedreichs-ataxia Last accessed: January 2024
  6. Spinal Muscular Atrophy (SMA) – A Brief Summary. SMA UK Available at: https://smauk.org.uk/support-information/about-sma/sma-summary/ Last accessed: January 2024
  7. Brunhilde Wirth, Spinal Muscular Atrophy: In the Challenge Lies a Solution, Trends in Neurosciences, Volume 44, Issue 4, 2021, Pages 306-322 Available at: www.sciencedirect.com/science/article/pii/S0166223620302745 Last accessed: January 2024.

Biogen-225544 | Date of preparation: January 2024